Canaccord Genuity initiated coverage on Tandem Diabetes Care with a new price target
$TNDM
Medical/Dental Instruments
Health Care
Canaccord Genuity initiated coverage of Tandem Diabetes Care with a rating of Buy and set a new price target of $57.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2024 | $46.00 | Neutral | Goldman |
| 10/2/2024 | $65.00 | Outperform | RBC Capital Mkts |
| 8/22/2024 | $45.00 | Equal-Weight | Morgan Stanley |
| 8/8/2024 | $57.00 | Buy | Canaccord Genuity |
| 5/30/2024 | $60.00 | Buy | Redburn Atlantic |
| 5/22/2024 | $40.00 → $57.00 | Neutral → Buy | Citigroup |
| 4/29/2024 | $21.00 → $45.00 | Equal Weight → Overweight | Wells Fargo |
| 4/25/2024 | $34.00 → $45.00 | Market Perform → Outperform | Leerink Partners |
10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday. Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its second-quarter core sales guidance. The company said it now projects core sales to be approximately $3.6 billion (vs. consensus of $3.41 billion), an increase from the previous guidance of $3.4 billion. Core EPS is expected to reach the high end of, or slightly exceed, the management's guided range of $0.42 to $0.46 (vs. estimate of $0.45). Corning shares jumped 9.4% to $42.05 on Monday. Here are some other big stocks recording gains in today’s session. Morphic Holding, Inc. (NASDA
In the latest quarter, 15 analysts provided ratings for Tandem Diabetes Care (NASDAQ:TNDM), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 6 3 0 0 Last 30D 0 1 0 0 0 1M Ago 4 0 0 0 0 2M Ago 1 5 1 0 0 3M Ago 1 0 2 0 0 Analysts have recently evaluated Tandem Diabetes Care and provided 12-month price targets. The average target is $48.8, accompanied by a high estimate of $75.00 and a low estimate of $31.00. Witnessing a posit
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time), Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 11:30am Eastern Time (8:30am Pacific Time), Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 4:30pm GMT (11:30am ET, 8:30am PT), and Wolfe Research Healthcare Conference on Wednesday, November 20, 2024 at 8:40am Eastern Time (5:40am Pacific Time). In addition, the
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close on Wednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). "High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Control-IQ technology,"1 said Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes Care. "Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time. We are proud to be able t
Goldman initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $46.00
RBC Capital Mkts initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $65.00
Morgan Stanley initiated coverage of Tandem Diabetes Care with a rating of Equal-Weight and set a new price target of $45.00
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close on Wednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2024 and increased sales guidance for the year ending December 31, 2024. Second Quarter 2024 Highlights Worldwide GAAP sales increased 13 percent to $221.9 million compared to second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to $221.8 million compared to second quarter 2023. More than 20,000 pumps shipped in the United States, a sequential increase of 33 percent compared to first quarter 2024. Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM) sensor integration in the Uni
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BIc1efe0f41c4149
For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)